Literature DB >> 1903183

Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor.

R A Ezekowitz1, D J Williams, H Koziel, M Y Armstrong, A Warner, F F Richards, R M Rose.   

Abstract

Human exposure to Pneumocystis carinii is common but, in the absence of acquired or genetic dysfunction of either cellular or humoral immunity, exposure rarely leads to illness. Although alveolar macrophages can degrade P. carinii, macrophage receptors involved in P. carinii recognition have not been clearly defined. Characterization of a predominant surface glycoprotein of the high mannose type led us to investigate the role of the macrophage mannose receptor in this process. We report here that binding and uptake of cultured rat P. carinii by human and rat alveolar macrophages is reduced by 90% in the presence of competitive inhibitors of mannose receptor activity and by adherence of alveolar macrophages to mannan-coated surfaces. Further, only those COS cells transfected with the human macrophage mannose receptor complementary DNA that express surface mannose receptors bind and ingest P. carinii. These studies establish that the macrophage mannose receptor is sufficient for uptake of P. carinii and emphasize the role of the alveolar macrophage in first-line host defence against P. carinii.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1903183     DOI: 10.1038/351155a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  127 in total

Review 1.  Genetics of surface antigen expression in Pneumocystis carinii.

Authors:  J R Stringer; S P Keely
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  Alveolar macrophages in neonatal mice are inherently unresponsive to Pneumocystis murina infection.

Authors:  Cathryn Kurkjian; Melissa Hollifield; J Louise Lines; Amy Rogosky; Kerry M Empey; Mahboob Qureshi; Stephen A Brown; Beth A Garvy
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

Review 3.  Extrapulmonary pneumocystosis.

Authors:  V L Ng; D M Yajko; W K Hadley
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

4.  In vivo targeting of alveolar macrophages via RAFT-based glycopolymers.

Authors:  Eun-Ho Song; Matthew J Manganiello; Yu-Hua Chow; Bilal Ghosn; Anthony J Convertine; Partick S Stayton; Lynn M Schnapp; Daniel M Ratner
Journal:  Biomaterials       Date:  2012-07-06       Impact factor: 12.479

5.  Cdc42 and RhoB activation are required for mannose receptor-mediated phagocytosis by human alveolar macrophages.

Authors:  Jianmin Zhang; Jinping Zhu; Xia Bu; Melanie Cushion; T Bernard Kinane; Hava Avraham; Henry Koziel
Journal:  Mol Biol Cell       Date:  2004-12-01       Impact factor: 4.138

6.  Characterization of major surface glycoprotein genes of human Pneumocystis carinii and high-level expression of a conserved region.

Authors:  Q Mei; R E Turner; V Sorial; D Klivington; C W Angus; J A Kovacs
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

7.  Induction of fibrinogen expression in the lung epithelium during Pneumocystis carinii pneumonia.

Authors:  P J Simpson-Haidaris; M A Courtney; T W Wright; R Goss; A Harmsen; F Gigliotti
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Candida albicans stimulates arachidonic acid liberation from alveolar macrophages through alpha-mannan and beta-glucan cell wall components.

Authors:  M Castro; N V Ralston; T I Morgenthaler; M S Rohrbach; A H Limper
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  The life cycle stages of Pneumocystis murina have opposing effects on the immune response to this opportunistic, fungal pathogen.

Authors:  Heather M Evans; Grady L Bryant; Beth A Garvy
Journal:  Infect Immun       Date:  2016-08-29       Impact factor: 3.441

10.  Trypanosoma cruzi amastigote adhesion to macrophages is facilitated by the mannose receptor.

Authors:  S Kahn; M Wleklinski; A Aruffo; A Farr; D Coder; M Kahn
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.